Accreditation/Credit Designation

Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Acknowledgment of Commercial Support

This activity is supported by an educational grant from Daiichi Sankyo.

Targeting HER2/3 in Advanced NSCLC: Where Are We and Where Are We Going?

Release Date: June 25, 2020
Expiration Date: June 25, 2021

Activity Overview

The HER2 mutation has been identified as an oncogenic driver in non–small cell lung cancer (NSCLC). HER2 amplification is a mechanism of acquired resistance to first-generation tyrosine kinase inhibitors (TKIs) in EGFR mutant-positive lung cancers. There has been progress in the development of EGFR-targeted therapies for lung cancers; however, intrinsic and acquired resistance remains a significant clinical challenge. Community clinicians who treat patients with HER2-altered NSCLC need to be up-to-date on the most accurate methods of diagnosis to effectively select frontline therapy and beyond to provide the best care to their patients.

This enduring CME activity is from a live webcast that was presented on June 16, 2020. Experts in NSCLC discussed testing strategies for HER2 alterations in a clinically applicable manner. The expert panel discussed current and emerging treatment options for HER2 alteration-positive NSCLC. Additionally, they addressed challenges experienced by clinicians in daily practice and the management of adverse events relating to HER2-targeted treatment.

Acknowledgment of Commercial Support

This activity is supported by an educational grant from Daiichi Sankyo.

Instructions for This Activity and Receiving Credit

  1. Complete the activity (including pre- and post-activity assessments).
  2. Answer the evaluation questions.
  3. Request credit using the drop-down menu.

You may immediately download your certificate.


Target Audience

This activity is intended for medical oncologists, pathologists, and other health care professionals interested in the latest advances in the treatment of patients with NSCLC. Fellows, researchers, nurses, nurse practitioners, physician assistants, and other healthcare professionals interested in the treatment of patients with NSCLC are also invited to participate.

Learning Objectives

Upon successful completion of this educational activity, you should be better prepared to:

  • Explain the rationale for testing HER2/3 in patients with advanced NSCLC.
  • Outline molecular testing strategies for the detection of HER2/3 in advanced NSCLC.
  • Consider data from clinical trials exploring HER2/3 targeted treatment for patients with advanced NSCLC.
  • Evaluate novel treatment strategies for patients with NSCLC and HER2/3 alterations.

Faculty, Staff, and Planners’ Disclosures

In accordance with ACCME Guidelines, PER® has identified and resolved all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.

Faculty

Hossein Borghaei, DO, MS
Hossein Borghaei, DO, MS
Professor and Chief, Thoracic Oncology
The Gloria and Edmund M. Dunn Chair in Thoracic Oncology
Fox Chase Cancer Center
Philadelphia, PA

Disclosures: Grant Research Support: Bristol Myers Squibb/Lilly, Merck/Celgene, Millennium; Consultant: AbbVie, Amgen, AstraZeneca, Axiom, Boehringer Ingelheim, BioNTech, Bristol Myers Squibb, Cantargia AB, Celgene, Daiichi Sankyo, EMD Serono, Genetech, Genmab, GLG Pharma, HUYABIO, Lilly, Merck, Novartis, Pfizer, PharmaMar, Regeneron, Takeda; Speakers Bureau: Sonnet BioTherapeutics, Rgenix (scientific advisory board); Other: Data and safety monitoring board: University of Pennsylvania, CAR T program, Incyte, Takeda.

Enriqueta Felip, MD, PhD
Enriqueta Felip, MD, PhD
Section Chief, Medical Oncology Department
Vall d’Hebron University Hospital
Head, Thoracic Oncology and H&N Cancer Unit
Vall d’Hebron Institute of Oncology
Professor of Medicine, UVic-UCC
Barcelona, Spain

Disclosures: Grant Research Support: Grant for Oncology Innovation; Consultant: Advisory Board: AbbVie, AstraZeneca, Blueprint Medicines, Boehringer Ingelheim, Bristol Myers Squibb, Eli Lilly, Quadrant Health, Janssen, Merck KGaA NSD, Novartis, Pfizer, Roche, Samsung, Takeda, GSK, Bayer; Speaker Bureau: AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Eli Lilly, NSD, Novartis, Pfizer, Roche, Takeda, touchIME; Other: Grifols (independent member of the board).

Mohammad Jahanzeb, MD, FACP
Mohammad Jahanzeb, MD, FACP
Chief Medical Oncology Scientific and Strategic Advisor
21st Century Oncology
Founder and Managing Partner
Florida Precision Oncology R&C, LLC
Boca Raton, FL

Disclosures: Grant Research Support: Lilly, Boehringer Ingelheim-Callisto, Takeda; Consultant: Novartis, Roche Genentech, Pfizer, Takeda, Puma, BMS, AstraZeneca, Merck; Speaker Bureau: Novartis, Roche Genentech, Pfizer, Takeda, Puma, BMS, AstraZeneca, Merck.

Maurice Pérol, MD Faculty Chair
Maurice Pérol, MD Faculty Chair
Head of Thoracic Oncology Program
Department of Medical Oncology
Léon Bérard Cancer Center
Lyon, France

Disclosures: Grant Research Support: Roche, AstraZeneca, Takeda, Boehringer lngelheim, Chugai; Consultant: Eli Lilly, Roche, AstraZeneca, Pfizer, Boehringer lngelheim, Bristol Myers Squibb, MSD, Takeda, Novartis; Speakers Bureau: Eli Lilly, Roche, AstraZeneca, Pfizer, Amgen, Boehringer lngelheim, Bristol Myers Squibb, MSD, Takeda, Novartis, Illumina.

David R. Spigel, MD
David R. Spigel, MD
Chief Scientific Officer
Lung Cancer Research Program Director
Sarah Cannon Research Institute
Nashville, TN

Disclosures: Grant Research Support: All to Institution: Aeglea BioTherapeutics, Astellas, AstraZeneca, BIND Therapeutics, Bristol Myers Squibb, Celgene, Celldex, Clovis, Daiichi Sankyo, Eisai, Lilly, EMD Serono, G1 Therapeutics, Genentech, GRAIL, ImClone Systems, ImmunoGen, Ipsen, Janssen, MedImmune, Merck, Molecular Partners, Nektar Therapeutics, Neon, Novartis, Takeda, Transgene; Consultant: All to Institution: Aptitude Health, AstraZeneca, Bayer, Bristol Myers Squibb, Celgene; Dracen Pharmaceuticals, EMD Serono, Evelo Biosciences, Genentech, GlaxoSmithKline, Iksuda Therapeutics, Illumina, Merck, Molecular Templates, Nektar Therapeutics, Novartis; Pfizer, PharmaMar, Roche, Seattle Genetics, Takeda, TRIPTYCH Health Partners, TRM Oncology, Williams and Connolly LLP.

The staff Physicians' Education Resource®, LLC (PER®) have no relevant financial relationships with commercial interests to disclose.

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a healthcare professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.


Login or Register to Start Activity

Please use the form below to Register or Log In to begin Activity.

*Required Fields
Calendar of Events
SUNMONTUESWEDTHURSFRISAT
  12345
6789101112
13141516171819
20212223242526
27282930
Filter By